TScan Therapeutics, Inc. (TCRX)
NasdaqGM
Fundamentals
Valuation and ratings
TScan Therapeutics, Inc. trades at USD0.79. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Super investor ownership
6 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$1.47M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$1.38M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$1.22M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$322.8K · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$321.6K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own TCRX?
6 of the institutions we track reported a position in TCRX in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
The full research page for TCRX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.